Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K16/10

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/002944ANTIBODY CAPABLE OF BINDING TO NOVEL CORONAVIRUS (SARS-COV-2) AND SARS CORONAVIRUS (SARS-COV)
WO 26.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/JP2022/027860 Applicant PUBLIC UNIVERSITY CORPORATION FUKUSHIMA MEDICAL UNIVERSITY Inventor WATANABE Shinya
[Problem] The present invention addresses the problem of providing a novel antibody that can prevent and/or treat SARS or COVID-19 infection. Provided is an antibody which comprises heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:1, heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:2, heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:3, light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:4, light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:5, and light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:6 and which is capable of binding to a receptor binding domain (RBD) of S1 subunit of SARS-CoV or SARS-CoV-2, or an antibody fragment of the antibody.
2.WO/2023/003679SINGLE DOMAIN ANTIBODIES THAT BIND AND NEUTRALIZE VENEZUELAN EQUINE ENCEPHALITIS VIRUS
WO 26.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2022/035483 Applicant THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY Inventor LIU, Jinny Lin
Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Venezuelan equine encephalitis virus (VEEV).
3.WO/2023/004295RECOMBINANT MICROORGANISMS AS A VERSATILE AND STABLE PLATFORM FOR PRODUCTION OF ANTIGEN-BINDING MOLECULES
WO 26.01.2023
Int.Class C12N 15/74
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
Appl.No PCT/US2022/073858 Applicant LANZATECH, INC. Inventor FACKLER, Nicholas Alexander
The disclosure provides genetically engineered microorganisms capable of producing antigen-binding molecules. Additionally, the disclosure provides engineered microorganisms comprising one or more disrupted genes to strategically divert carbon flux away from undesirable products towards products, and optionally co-products, of interest. Further, the disclosure enables co-production of useful chemicals from gaseous substrates.
4.WO/2023/004431CHARACTERIZATION OF POTENT AND BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SARS-COV-2, ITS VARIANTS, AND RELATED CORONAVIRUSES AND METHODS OF USE
WO 26.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2022/074075 Applicant THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK Inventor HO, David, D.
The subject matter described herein relates to engineered monoclonal antibodies, derived from antibodies isolated from human patients, neutralizing a SARS-CoV-2 virus, its variants, or related coronaviruses.
5.WO/2023/001736ENGINEERED ANTI-SARS COV-2 IgG3 ANTIBODIES
WO 26.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2022/070005 Applicant UNIVERSITÄT FÜR BODENKULTUR WIEN Inventor STEINKELLNER, Herta
The present invention refers to a recombinant anti-SARS CoV-2 antibody with enhanced viral neutralization potency comprising an lgG3 constant and hinge region with one or more engineered glycans. The invention refers also to a nucleic acid encoding the anti-SARS CoV-2 antibody, plant cells expressing the anti-SARS CoV-2 antibodies, a method for production of anti-SARS CoV-2 antibody, and a pharmaceutical composition comprising anti-SARS CoV-2 antibody. The invention also refers to the use of an anti-SARS CoV-2 antibody for detecting SARS CoV-2 in a sample, the use for the manufacture of a medicament, and the use for treating or preventing diseases associated with coronavirus infections.
6.WO/2023/288078CORONAVIRUS ANTIBODIES AND USES THEREOF
WO 19.01.2023
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2022/037330 Applicant INTERNATIONAL AIDS VACCINE INITIATIVE INC. Inventor SOK, Devin
This application provides compositions and methods for treating, preventing, or reducing the progression rate and/or severity of COVID-19, particularly treating, preventing or reducing the progression rate and/or severity of one or more COVID-19-associated complications.
7.WO/2023/285620COMPOSITIONS AND METHODS FOR TARGETING VIRAL PROTEINS
WO 19.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2022/069796 Applicant ALCHEMAB THERAPEUTICS LTD. Inventor GALSON, Jacob Daniel
The present disclosure provides one or more polypeptides, proteins antibodies or antibody fragments useful in the diagnosis, prophylaxis (pre- or post-exposure), or treatment of Covid-19.
8.WO/2023/287875ANTI-SARS-COV-2-SPIKE GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO 19.01.2023
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/US2022/036950 Applicant REGENERON PHARMACEUTICALS, INC. Inventor BAUM, Alina
The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
9.WO/2023/287815COMPOSTIONS AND TREATMENTS FOR CORONAVIRUS INFECTIONS
WO 19.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2022/036857 Applicant OHIO STATE INNOVATION FOUNDATION Inventor AMER, Amal
Disclosed are methods for assessing the severity of a coronavirus infection through the measurement of caspase 4 and methods of treating a coronavirus infection comprising administering to an infected subject an inhibitor of CASP4 or its downstream effectors IL-1 B, Cxcl1, or Willebrand factor (vWF). The coronaviral infection may be a SARS-CoV-2 variant.
10.WO/2023/279803PROTEIN BINDING MOLECULE OF RBV AND USE THEREOF
WO 12.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2022/087557 Applicant GAO, Guang Inventor GAO, Guang
Provided is a protein molecule for preventing or treating rabies virus (RBV) infection related diseases, comprising a protein binding molecule for RBV screened by using phage display library technology. The protein molecule aims at a G protein of RBV, and the molecule contains an antibody of an immunoglobulin single variable structural domain.